Greenbrook Tms Inc

GBNH

$

Closing

1D

YTD

Market cap

$

52 week high

$

52 week low

$

Volume

Check if the stock is halal

Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.

Get started from just $3.99/month

Market cap

$

Analysts' Rating

BUY

Price Target (Mean)

0.65

Total Analysts

1

P/E

Operating Margin

-46.38%

Beta

Revenue Growth (Annual)

32.39%

52 week high

$

52 week low

$

Div. Yield

%

EPS Annual Growth

0.00

Note on Purification and Zakat

  • Purification and Zakat (for long-term investing) calculations are in USD per share and based on AAOIFI methodology. AAOIFI requires purification every financial period (e.g. quarterly). 
  • If you follow S&P Shariah’s Dividend-only purification, then remove the impure income % from the dividends you receive. No purification required for non-dividend paying stocks, according to S&P Shariah.
  • For Zakat, if you did not invest in a company from a long term perspective, then consider the shares as trading goods and give 2.5% of the total value if a year has passed on them. 

Company Profile

Greenbrook TMS Inc. is a provider of Transcranial Magnetic Stimulation (TMS) therapy and Spravato (esketamine nasal spray) therapy in the United States for the treatment of depressive disorder (MDD) and other mental health disorders. TMS therapy provides local electromagnetic stimulation to specific brain regions known to be directly associated with mood regulation. Spravato is offered to treat adults with treatment-resistant depression and depressive symptoms in adults with MDD with suicidal thoughts or actions. The Company operates a network of outpatient mental health service centers that specialize in Treatment across the United States. It offers Treatment Centers in convenient locations to provide easy access to patients and clinicians. The Company owns and operates 133 Treatment Centers in the Commonwealths of Massachusetts, Virginia and Pennsylvania and the States of Maryland, North Carolina, Missouri, Illinois, Ohio, Texas, Connecticut, Florida, and South Carolina.